Patient-reported outcomes and complications during head and neck cancer radiotherapy before versus during the COVID-19 pandemic

Sarah Nicole Hamilton1,2 · Nicole Chau1,2 · Eric Berthelet1,2 · Jonn Wu1,2 · Eric Tran1,2 · Melanie Chevrier1 · Victoria Lau1 · Matthew Chan1,2 · Kimberly DeVries1 · Vincent LaPointe1 · Robert A. Olson2,3,4

Received: 14 September 2021 / Accepted: 15 November 2021 / Published online: 26 November 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract
Purpose This study compares patient-reported outcomes and treatment-related complications during radiotherapy before (August 2019–January 2020) versus during (March–Sept 2020) the COVID-19 pandemic.

Materials and methods The MD Anderson Symptom Inventory-head and neck module was used to assess curative intent in H&N cancer patients’ symptoms during radiotherapy.

Results There were 158 patients in the pre-pandemic cohort and 137 patients in the pandemic cohort. There was no significant difference in enteral feeding requirements between the cohorts (21% versus 30%, \( p = 0.07 \)). Weight loss was higher during the pandemic (mean −5.6% versus 6.8%, \( p = 0.03 \)). On multivariate analysis, treatment during the pandemic was associated with higher symptom scores for coughing/choking while eating (2.7 versus 2.1, \( p = 0.013 \)).

Conclusions Complication rates during H&N radiotherapy during the COVID-19 pandemic were similar at our institution relative to the pre-pandemic era, although weight loss was greater and patients reported more severe choking/coughing while eating.

Keywords Head and neck cancer · Radiotherapy · COVID-19 · Patient-reported outcomes · Treatment toxicity

Introduction
Radiotherapy is commonly used for the treatment of head and neck (H&N) cancer. Radical radiotherapy is associated with significant cumulative acute side effects including severe mucositis, pain, dysgeusia, dysphagia, and weight loss [1]. The substantial toxicity from H&N radiotherapy can have significant impacts on patients’ quality of life and is associated with a high risk of treatment-related morbidity and mortality [1–5]. The COVID-19 outbreak began in mid-March 2020 in Canada, leading to an unprecedented shutdown of non-essential services in the province of British Columbia. However, BC Cancer continued to provide essential radiotherapy for patients with H&N cancer per our standard of care and radiation oncologists continued to evaluate these patients in person during their radiation treatment. Despite this, several support services were not consistently available throughout the pandemic, such as volunteer driver support to attend appointments, in-person patient and family counseling sessions, speech language pathology instrumental assessments, and reduced cost housing for out of town patients. Additionally, many patients had reduced personal and family support available due to social distancing measures in place. Furthermore, access to in-person visits with family physicians and specialists was limited. Some patients presented with more locally advanced disease, due to delays in diagnosis during the pandemic [6].

Due to the above factors, it was our clinical perception that a higher proportion of our patients developed greater toxicities during the COVID-19 pandemic. Therefore, we
aimed to compare patient-reported outcomes (PROs) and complications during H&N radical radiotherapy for patients undergoing treatment from March 2020 to Sept 2020, relative to the preceding period from Aug 2019 to Jan 2020. This was performed to assess if the rate of treatment-related complications was higher and PROs were worse during the COVID-19 pandemic and to have a better understanding of the pandemic’s impact on H&N patients’ quality of life during radiotherapy.

**Materials and methods**

The Prospective Outcomes and Support Initiative (POSI) collects PROs across all tumor sites at our multi-center institution [8]. Patients undergoing radical radiotherapy for H&N cancer to any subsite complete the MD Anderson Symptom Inventory for head and neck cancer module (MDASI-HN) on the day of their radiation planning scan using an iPad as the baseline assessment [9–11]. The MDASI-HN is a H&N cancer-specific questionnaire that contains the core MDASI’s 13 symptom and 6 Interference questions with an additional 9-symptom questions relevant to H&N cancer. Each symptom is scored on a scale of zero to ten, with ten being the most severe [11]. Each week during radiotherapy, patients are provided the iPad to repeat the MDASI-HN questionnaire (weekly surveys). Data was retrieved for patients who started radiotherapy over a 1-year period from August 1, 2019, to September 31, 2020. For the purpose of this study, patients were analyzed based on two distinct time periods: those who both started and completed radiotherapy before the COVID-19 pandemic (pre-COVID cohort, August 2019 to Jan 2020) relative to those who started and completed radiotherapy during the COVID-19 pandemic (March 2020 to September 2020). Patients who received palliative radiotherapy were excluded, as well as those patients who started pre-pandemic (Feb 2020) and completed radiotherapy during the pandemic (Mar 2020). Patients who did not complete a baseline questionnaire and at least one weekly questionnaire were excluded from the PRO analysis. The results of the PROs were available via an electronic interface to review before each weekly patient review appointment; review of the results and discussion with patients were at the discretion of the treating radiation oncologist.

Clinical, pathologic, and treatment data were abstracted retrospectively. Variables abstracted included age at diagnosis, sex, tumor site, T-stage, N-stage, smoking status, alcohol usage, Eastern Cooperative Oncology Group (ECOG) performance status, surgery, radiation dose, and use of concurrent chemotherapy. Acute complications during radiotherapy were also abstracted by review of the physician and allied health narrative notes in the electronic medical record. These included enteral feeding (NG tube, prophylactic G-tube, reactive G-tube), percentage weight loss, aspiration pneumonia, and hospitalization.

**Treatment details**

Patients were treated with Volumetric Arc Therapy (VMAT) radiotherapy techniques to 70 Gray (Gy) in 35 fractions. Some patients received altered fractionation schedules including 55 Gy in 20 fractions (early larynx cancers only), 60 Gy in 25 fractions, and 66 Gy in 30 fractions to gross disease. Post-operative patients received 60 to 66 Gy in 30 to 33 fractions. Concurrent chemotherapy was used for patients with locally advanced disease (T3+, N+ for definitive therapy and post-operatively for extra nodal extension or positive margins. Cisplatin weekly (40 mg/m²) or every 3 weeks (100 mg/m²) was used, or cetuximab (400 mg/m² loading dose day–7, 250 mg/m² weekly) for patients with contraindications to cisplatin. There were no changes to the above treatment recommendations (dose, fractionation, usage of concurrent chemotherapy) during the COVID-19 pandemic.

**Data analysis**

Baseline patient, disease and treatment characteristics, and complication rates were compared between the two cohorts using chi-square test and independent sample t-test.

The 28-symptom scores of the MDASI-HN were analyzed across 7 weekly questionnaires completed during radiotherapy. Subscale score totals were calculated based on the arithmetic mean of items in the subscale: Core symptoms—question 1–13, H&N module symptoms—question 14–22, and Interference—question 23–28. When calculating subscale scores, a majority of the subscale’s items must have been responded to (i.e., 7 of the 13 Core symptom severity items, 5 of the 9 H&N module symptom items, or 4 of the 6 Interference items would represent the majority of the items for the subscales). If the patient responded to fewer than half of the subscale’s items at a given assessment, the subscale total for that weekly assessment was considered missing [11]. The primary endpoint of the study was to compare the mean average score for each symptom and subscale scores pre-COVID versus during COVID. This was done using the independent sample t-test with Bonferroni correction for multiple comparisons. Group differences were considered significant if p < 0.002 for the 28 individual symptom items and p < 0.02 for the 3 subscale score totals.

Secondary endpoints were to use linear mixed models to assess trends in symptom progression over time and test cohort group effects in symptom severity for each
MDASI-HN individual symptom item and three overall symptom subscale scores. Mixed models were used due to the presence of repeated measures data, where data collected at one point in time is not independent of the data collected at another time in the study, and due to the capability of analyzing data with missing values. Univariate linear mixed models were fit with time and cohort as fixed effects and patients as random effects to examine the effect on mean symptom severity for each individual symptom question or subscale total as the outcome. Multivariate linear mixed models were used to evaluate correlates of symptom severity for the most prominent MDASI-HN symptom questions (i.e., those showing the highest symptom severity difference between cohort groups in univariate analysis). The three symptom outcomes analyzed were Q12—vomiting, Q16—choking/coughing while eating, and Q21—mouth/throat sores. Correlates of symptom severity were also analyzed for overall symptom subscale scores (Core, H&N, Interference) on multivariate analysis using linear mixed models. Multivariate linear mixed models were fit with time, cohort, and covariates of interest as fixed effects and patients as random effects to examine the influence on mean symptom severity. Covariates were selected for inclusion based on clinical importance and statistical significance and included age at treatment, sex, smoking status, alcohol use, ECOG performance status, percent weight loss, T-stage, N-stage, tumor site, receipt of chemotherapy, surgery, and radiation dose. Interaction effects were also tested to determine if the effect of symptom severity over time varied between cohort pre/during COVID time periods.

Statistical analysis was performed using SAS version 9.4 (SAS Institute Inc., Cary, NC). P-values of <0.05 were considered statistically significant, unless otherwise noted when Bonferroni corrections were used, and all tests were two-tailed. The study was approved by our institutional research ethics board.

Results

Patient cohorts

Table 1 shows the baseline characteristics of the pre-COVID and during COVID cohorts. Mean age, sex distribution, ECOG status, and alcohol usage were similar between the cohorts (p > 0.05). There were more current smokers during the COVID pandemic (20% versus 10%, p = 0.03). T-stage, N-stage, and tumor site distribution were similar pre-COVID and during COVID. More patients received concurrent chemotherapy during COVID (58% versus 42%, p = 0.03) but radiation doses and usage of surgery were similar between the cohorts.

Complication rate

Complication rates were similar pre- versus during COVID (Table 2). There were more patients requiring enteral feeding during COVID (30% versus 21%), but this did not reach statistical significance (p = 0.07). The mean percentage weight loss was higher during the pandemic at 6.8% loss compared to baseline versus 5.6% pre-pandemic (p = 0.03). Rates of aspiration pneumonia and hospitalization during radiotherapy were similar pre- versus during COVID. No patients in our study developed documented COVID-19 infection during radiotherapy.

MDASI-HN compliance

Of the 295 patients included in the study, 278 patients completed a baseline questionnaire and at least one weekly assessment during radiation; these patients were included for subsequent analysis. Four or more weekly questionnaires (of 7) were completed by 236/278 patients (85%). The average number of weekly questionnaires completed was 5 (range: 1–8).

Symptom severity

Mean average symptom scores (across the duration of radiation treatment) were highest (maximum score = 10) for tasting food (5.06), dry mouth (4.46), fatigue/tiredness (4.33), swallowing/chewing (4.31), lack of appetite (4.07), and pain (3.89). Similarly, mean maximum symptom scores (maximum symptom score at any time during radiation treatment) were highest for tasting food (6.80), swallowing/chewing (6.20), dry mouth (6.10), lack of appetite (5.97) fatigue/tiredness (5.88), and pain (5.77).

Mean average symptom scores and subscale scores comparing pre-COVID versus during COVID scores are shown in Table 3.

Univariate linear mixed model analysis

The results of the mixed model analyses indicate that all symptom scores, within subject tests, reveal a significant time effect: symptom severity became significantly worse over the duration of radiotherapy (all p < 0.0001). Select between cohort symptom scores are shown in Fig. 1. There were three symptom scores with a significant cohort effect detected, with higher symptom scores during COVID versus pre-COVID. These included vomiting (p = 0.01), choking/coughing while eating (p = 0.007), and mouth/throat sores (p = 0.04). Figure 2 shows the mean symptom scores
for the Core, H&N, and Interference subscales during COVID versus pre-COVID. The scores were significantly higher for the H&N subscale during COVID versus pre-COVID ($p = 0.04$).

### Table 1

| Characteristic                  | Pre-COVID Cohort | During COVID Cohort | $p$-value |
|---------------------------------|------------------|---------------------|-----------|
| **Demographics**                |                  |                     |           |
| Mean age (range)                | 63.8 years (26–91 years) | 63.2 years (27–94 years) | 0.48      |
| Sex                             |                  |                     |           |
| Male                            | 126 (80%)        | 105 (77%)           | 0.52      |
| Female                          | 32 (20%)         | 32 (23%)            |           |
| Smoking status                  |                  |                     |           |
| Lifelong non-smokers            | 72 (46%)         | 56 (41%)            |           |
| Ex-smoker (quit ≥1 year ago)    | 71 (45%)         | 53 (39%)            | 0.03      |
| Current smokers (quit <1 year ago) | 15 (10%)      | 28 (20%)            |           |
| Alcohol use                     |                  |                     |           |
| Yes                             | 37 (23%)         | 37 (27%)            | 0.50      |
| No                              | 121 (77%)        | 100 (73%)           |           |
| ECOG                            |                  |                     |           |
| 0                               | 51 (32%)         | 58 (42%)            | 0.27      |
| 1                               | 91 (58%)         | 65 (47%)            |           |
| 2                               | 12 (8%)          | 9 (7%)              |           |
| 3                               | 4 (3%)           | 5 (4%)              |           |
| **Disease factors**             |                  |                     |           |
| T-stage                         |                  |                     |           |
| T1/T2                           | 90 (57%)         | 78 (57%)            | 0.99      |
| T3/T4                           | 68 (43%)         | 59 (43%)            |           |
| N-stage                         |                  |                     |           |
| Node-negative                   | 50 (32%)         | 34 (25%)            | 0.19      |
| Node-positive                   | 108 (68%)        | 103 (75%)           |           |
| **Tumor site**                  |                  |                     |           |
| Oropharynx                      | 70 (44%)         | 65 (47%)            | 0.18      |
| Larynx/hypopharynx              | 29 (19%)         | 14 (11%)            |           |
| Nasopharynx/paranasal sinus     | 23 (14%)         | 16 (12%)            |           |
| Oral cavity                     | 17 (11%)         | 21 (15%)            |           |
| Salivary gland                  | 7 (4%)           | 10 (7%)             |           |
| Thyroid                         | 6 (4%)           | 3 (2%)              |           |
| Other/primary unknown           | 6 (4%)           | 6 (4%)              |           |
| **Treatment factors**           |                  |                     |           |
| Concurrent chemotherapy          |                  |                     |           |
| None                            | 92 (58%)         | 57 (42%)            | 0.03      |
| Cisplatin 100 mg/m² q3 weekly   | 21 (13%)         | 13 (10%)            |           |
| Cisplatin 40 mg/m² weekly       | 44 (28%)         | 63 (46%)            |           |
| Cetuximab                       | 1 (1%)           | 4 (3%)              |           |
| Surgery                         |                  |                     |           |
| Yes                             | 59 (37%)         | 57 (42%)            | 0.46      |
| No                              | 99 (63%)         | 80 (58%)            |           |
| Mean total dose (range)         | 66 Gy (50–70 Gy) | 67 Gy (50–70 Gy)    | 0.34      |

Italic indicate $p$ value <0.05

**Multivariate linear mixed model analysis**

Results of multivariate mixed model analyses indicate that symptom severity becomes significantly worse over time for...
Table 2 Complications pre-COVID-19 pandemic versus during COVID-19 pandemic

| Characteristic          | Pre-COVID Cohort n (%) | During COVID Cohort n (%) | p-value |
|-------------------------|------------------------|---------------------------|---------|
| Prophylactic G-tube     | 8 (5%)                 | 11 (8%)                   | 0.30    |
| Reactive G-tube         | 17 (11%)               | 20 (15%)                  | 0.32    |
| Nasogastric tube        | 11 (7%)                | 10 (7%)                   | 0.91    |
| Any enteral feeding     | 33 (22%)               | 42 (31%)                  | 0.07    |
| Mean percentage weight  | 8.0 ± 11.2             | 9.5 ± 12.5                |         |
| Greater than 10% weight loss | 34 (22%) | 42 (31%) | 0.07 |
| Aspiration pneumonia    | 10 (6%)                | 4 (3%)                    | 0.17    |
| Hospitalization         | 24 (15%)               | 21 (15%)                  | 0.97    |

Bold indicates p value < 0.05

all symptoms evaluated (all p < 0.0001).

I. Q12—Vomiting

Symptoms of vomiting became significantly worse over time for all patients (p < 0.0001). Node positivity was associated with higher mean symptom severity (1.7 versus 1.1, p = 0.026). Paranasal sinus/nasopharynx tumor sites (versus salivary gland) were associated with higher mean symptoms of vomiting (2.1 versus 0.8, p = 0.016). Non-smokers (1.2 versus 1.9 p = 0.033) and ex-smokers (1.3 versus 1.9 p = 0.046) had less severe symptoms of vomiting compared to current smokers, and patients who experienced less weight loss reported lower vomiting scores (p = 0.0006). Treatment pre-versus during the COVID pandemic was not associated with vomiting score on multivariable analysis (p = 0.12).

II. Q16—Choking/coughing while eating

Symptoms of choking/coughing while eating became significantly worse over time for all patients (p < 0.0001). Treatment during COVID compared to pre-COVID was associated with higher choking/coughing scores (2.7 versus 2.1, p = 0.013). Higher mean scores were reported for female patients (2.8 versus 2, p = 0.01) and those with node-positive disease (2.8 versus 2, p = 0.01), whereas patients with reduced weight loss (p = 0.008) and higher doses of RT (p = 0.032) had less severe symptoms of choking/coughing.

III. Q21—Mouth/throat sores

Symptoms of mouth/throat sores became significantly worse over time for all patients (p < 0.0001). Node positivity was associated with greater mean severity of mouth sores (4.4 versus 2.9, p < 0.0001). The cohort * time interaction remained significant in the multivariate model for mouth/throat sores (p = 0.019) indicating the severity of the symptom may be experienced differently for patients treated during COVID compared to pre-COVID (i.e., although mouth sores are becoming worse over time for all patients, the severity is changing at different rates for the two cohorts). Treatment pre-versus during the COVID pandemic was not associated with mouth/throat sore severity on multivariable analysis (p = 0.09).

IV. Core symptom subscale

Overall core symptoms became significantly worse over time for all patients (p < 0.0001). Node positivity was associated with higher mean core symptoms (3.7 versus 2.9, p = 0.001). Paranasal sinus/nasopharynx tumor sites (versus salivary gland) was associated with higher mean core symptom scores (p = 0.012). Patients who experienced less weight loss (p = 0.002) and had better performance status (ECOG 0/1 versus 2/3; 2.9 versus 3.7 p = 0.036) reported lower mean core symptoms. Treatment pre-versus during the COVID pandemic was not associated with core symptom severity on multivariable analysis (p = 0.27).

V. H&N symptom subscales

H&N symptoms became significantly worse over time for all patients (p < 0.0001). Node positivity was associated with symptom severity (4.2 versus 3.2, p = 0.0001). Paranasal sinus/nasopharynx tumor sites (versus salivary gland) was associated with more severe H&N symptoms (4.2 versus 3, p = 0.026). Patients who experienced less weight loss (p = 0.0001) and had better ECOG (ECOG 0/1 versus 2/3; 3.2 versus 4.1, p = 0.015) reported lower mean H&N symptoms. Treatment pre-versus during the COVID pandemic was not associated with H&N subscale symptom severity on multivariable analysis (p = 0.12).

VI. Interference subscale

Overall symptoms of interference became significantly worse over time for all patients (p < 0.0001). Node positivity was associated with higher mean symptom severity (4.2 versus 3.1, p = 0.001). Paranasal sinus/nasopharynx tumor sites (versus salivary gland) was significantly associated with higher mean interference symptoms (4.7 versus 2.7, p = 0.003). Patients with better ECOG performance (ECOG 0/1 versus 2/3) have lower mean interference symptom scores (3 versus 4.3, p = 0.008) Treatment pre-versus during the COVID pandemic was not associated with interference severity on multivariable analysis (p = 0.68).
Discussion

This study is the first, to our knowledge, evaluating patient-reported outcomes during radical radiotherapy for H&N cancer, comparing patients treated pre-COVID-19 pandemic versus during the COVID-19 pandemic. The two cohorts were very similar at baseline with respect to demographics, clinical variables, and treatment variables, although there were more smokers and usage of chemotherapy in the COVID-19 era. Patients reported more severe choking and coughing while eating during the COVID-19 pandemic and had a greater percentage weight loss from baseline. There were no significant differences between treatment cohorts for any of the other symptom outcomes examined in multivariate analysis.

During the COVID-19 pandemic, several organizations suggested possible mitigation strategies including using concurrent chemoradiotherapy if there are prolonged operating room closures and altering radiation-dose fractionation schedules to a shorter hypofractionated course [7, 12, 13]. At our institution, we did not change our standard of care treatment recommendations during the

| Question | Symptom | Pre-COVID cohort | During COVID cohort | p-value |
|----------|---------|------------------|---------------------|---------|
|          |         | Mean  | SD   | Mean  | SD   |         |
| 1        | Pain    | 3.75  | 2.29 | 4.05  | 2.32 | 0.27    |
| 2        | Fatigue/tiredness | 4.15  | 2.23 | 4.54  | 2.31 | 0.16    |
| 3        | Nausea  | 2.23  | 2.32 | 2.59  | 2.30 | 0.19    |
| 4        | Disturbed sleep | 3.41  | 2.35 | 3.60  | 2.40 | 0.49    |
| 5        | Distressed/upset | 2.63  | 2.17 | 3.03  | 2.42 | 0.15    |
| 6        | Shortness of breath | 1.65  | 1.98 | 1.72  | 2.09 | 0.77    |
| 7        | Remembering things | 2.00  | 1.96 | 2.21  | 1.95 | 0.36    |
| 8        | Lack of appetite | 3.81  | 2.69 | 4.38  | 2.46 | 0.068   |
| 9        | Drowsy/sleepy | 3.48  | 2.26 | 3.95  | 2.31 | 0.090   |
| 10       | Dry mouth | 4.39  | 0.21 | 4.55  | 0.22 | 0.60    |
| 11       | Feeling sad | 2.19  | 2.25 | 2.71  | 2.48 | 0.072   |
| 12       | Vomiting | 0.88  | 1.55 | 1.40  | 1.98 | 0.017   |
| 13       | Numbness/tingling | 1.29  | 1.80 | 1.45  | 1.78 | 0.47    |
| 14       | Mucus | 3.62  | 2.44 | 4.02  | 2.60 | 0.19    |
| 15       | Swallowing/chewing | 4.08  | 2.44 | 4.58  | 2.42 | 0.092   |
| 16       | Choking/coughing | 1.83  | 1.97 | 2.49  | 2.01 | 0.0065  |
| 17       | Voice/speech | 3.00  | 2.50 | 3.13  | 2.42 | 0.68    |
| 18       | Skin pain/burning/rash | 2.41  | 2.07 | 2.81  | 2.06 | 0.11    |
| 19       | Constipation | 2.65  | 2.31 | 2.83  | 2.42 | 0.54    |
| 20       | Tasting food | 4.84  | 3.19 | 5.31  | 2.66 | 0.18    |
| 21       | Mouth/throat sores | 3.14  | 2.45 | 3.73  | 2.39 | 0.04    |
| 22       | Teeth/gums | 2.09  | 2.17 | 2.59  | 2.25 | 0.06    |
| 23       | General activity | 3.40  | 2.41 | 3.61  | 2.57 | 0.48    |
| 24       | Mood | 2.81  | 2.27 | 3.27  | 2.48 | 0.11    |
| 25       | Work/housework | 3.54  | 2.65 | 3.65  | 2.58 | 0.71    |
| 26       | Relations | 2.35  | 2.25 | 2.55  | 2.31 | 0.47    |
| 27       | Walking | 2.49  | 2.28 | 2.54  | 2.37 | 0.87    |
| 28       | Enjoyment of life | 3.48  | 2.52 | 3.76  | 2.73 | 0.38    |
|          | Interference |         |       |       |       |         |
| 23       | General activity | 3.40  | 2.41 | 3.61  | 2.57 | 0.48    |
| 24       | Mood | 2.81  | 2.27 | 3.27  | 2.48 | 0.11    |
| 25       | Work/housework | 3.54  | 2.65 | 3.65  | 2.58 | 0.71    |
| 26       | Relations | 2.35  | 2.25 | 2.55  | 2.31 | 0.47    |
| 27       | Walking | 2.49  | 2.28 | 2.54  | 2.37 | 0.87    |
| 28       | Enjoyment of life | 3.48  | 2.52 | 3.76  | 2.73 | 0.38    |
|          | Subscale totals |       |       |       |       |         |
| 1–13     | Core symptoms | 2.74  | 1.62 | 3.08  | 1.73 | 0.093   |
| 14–22    | H&N Module symptoms | 3.05  | 1.74 | 3.49  | 1.82 | 0.042   |
| 23–28    | Interference | 2.99  | 2.17 | 3.18  | 2.30 | 0.46    |

Symptom severity differences between cohorts were compared using independent t-tests with Bonferroni correction. Group differences were considered significant if \( p < 0.002 \) for the 28 individual symptom items and \( p < 0.02 \) for the 3 subscale totals.
COVID-19 pandemic. In the ASTRO-ESTRO guidelines published by Thomson et al., there was strong agreement to modify the weekly in-person on-treatment reviews for H&N patients during radiotherapy [12]. One quarter of respondents (23%) had stopped in-person reviews completely, and others had reduced the weekly frequency of in-person appointments, replacing them with telephone (50%) or video (26%) reviews instead [12]. At our institution, we continued in-person radiation oncology visits for all weekly on treatment visits for H&N cancer patients, as they were already present in the radiotherapy department, unless the patient requested a virtual appointment, which was very uncommon. It is possible this contributed to the similar PROs as pre-pandemic, as symptoms were continued to be evaluated and managed in person with accompanying physical examination by radiation oncologists weekly. A proportion of medical oncology, dietician, and speech language pathology appointments were performed virtually during the pandemic.

The incidence of complications during radiotherapy such as unplanned hospitalization, aspiration pneumonia, and enteral feeding requirements were similar during the pandemic versus pre-pandemic. However, patients did have a greater mean percentage weight loss relative to their baseline during the COVID-19 pandemic. During the pandemic, patients continued to have a weekly consultation with a registered dietician. These appointments were a mix of in-person versus telephone appointments. The difference in mean weight loss between the cohorts was only 1.2%, and this may not be considered a clinically relevant finding given the small absolute difference. A potential explanation is that during the pandemic, many patients had less in-person support from their family and friends due to social distancing regulations that were in place. A previous study

Fig. 1 Mean symptom scores pre-COVID versus during COVID for select individual symptoms by week of radiotherapy

Fig. 2 Mean symptom scores pre-COVID versus during COVID for Core symptoms, H&N symptoms, and Interference by week of radiotherapy
showed that greater than 10% weight loss was associated with lower social contact scores [15]. None of the patients in our cohort developed COVID-19 infection, and prior studies have shown a mortality rate of 18.9% in head and neck cancer patients on active treatment [16].

On both univariate and multivariate analysis, receiving radiation during the COVID-19 pandemic was associated with higher patient-reported choking/coughing while eating relative to pre-pandemic. Before the pandemic, all patients at our institution had a pre-treatment in-person speech language pathology (SLP) consultation with a bedside swallowing assessment. Patients were then seen in person, weekly or biweekly during radiotherapy, and instrumental assessments (VFSS and FEES) were performed as appropriate. During the pandemic, patients were seen via Zoom or telephone pre-treatment and weekly or biweekly during treatment. It is possible that the sensitivity of detecting worsening dysphagia via verbal communication alone was reduced. This may also be more likely in a population such as H&N patients who may be experiencing difficulties with speech due to mucositis, hoarseness, and pain. Obtaining VFSS and FEES instrumental assessments was also greatly limited during the pandemic, based on published recommendations, due to the risk of COVID transmission during aerosol-generating medical procedures and limited fluoroscopic room availabilities [17]. Finally, pre-pandemic, the multidisciplinary group met weekly to discuss challenging cases, which alerted the SLP team earlier to patients struggling with new or worsening dysphagia. During the pandemic, multidisciplinary group meetings were not scheduled during the study era; however, they were later established in a virtual format to provide better team-based care [18].

To date, there have been very few published studies evaluating the quality of life of head and neck cancer patients during the COVID-19 pandemic. In a survey by Gallo et al., 121 H&N cancer patients were compared to a historical cohort [19]. They found that during the pandemic, H&N cancer survivors reported worse social functioning, physical functioning, and dyspnea relative to a similarly matched historical cohort. We did not see these differences in our cohort, based on the shortness of breath symptom assessment and Interference subscales; however, Gallo et al. used the EORTC QLQ-C30 measure, which cannot be directly compared to MDASI-HN. Additionally, this population of patients was post-treatment, whereas our population included only those on active radiotherapy [19]. A large study of cancer patients with a variety of tumor subsites, including 77 head and neck cancer patients, reported the majority of patients were very concerned about the impact of COVID-19 on their cancer treatment, highlighting the importance of psychosocial support needed during the pandemic [20].

Several studies have shown a delay in diagnosis and treatment of head and neck cancer during the pandemic [6, 7, 21–23]. There are several potential explanations for this, including patients’ fear of attending hospitals or physicians’ offices, reduced in-person consultations and specialist availability, and reduced operating room availability and post-anesthesia care for complex head and neck cancer surgeries [6, 7, 21, 22]. Increased time to surgery in head and neck cancer is associated with higher morbidity and mortality [22]. It is possible that the patients in our study treated during the COVID-19 pandemic experienced delays in diagnosis. However, the stage and tumor site distributions and ECOG status were similar in both cohorts, and delays in diagnosis are beyond the evaluation and objectives of this particular study.

Our study has both strengths and limitations. To our knowledge, this is the first study comprehensively comparing patient-reported outcomes and complications between a large cohort of head and neck cancer patients undergoing radiotherapy pre-COVID-19 relative to during COVID-19 and comprehensively following the trajectory of symptoms during radiotherapy. Limitations to our study include that given the variability of COVID-19 incidence and impact across the globe and subsequent impact on oncologic care (operating room time, availability of in-person assessments, and provision of multidisciplinary care), our results may not have external validity to other institutions. Additionally, we did not evaluate the impact of potential delay in diagnosis during the COVID-19 pandemic and subsequent influence on patient-reported outcomes, as this was outside the focus of this study. Finally, the differences in dysphagia and weight loss could have been influenced by differing smoking rates and chemotherapy usage between the cohorts. We were not able to assess current smoking rates during radiotherapy, as this data was not routinely collected, and this is known to influence acute toxicity.

In conclusion, head and neck cancer patients at our institution during the COVID-19 pandemic were similar at baseline relative to patients treated pre-COVID-19 pandemic. During the pandemic, on-treatment reviews were continued by radiation oncologists in person, but many support services were shifted to telehealth to maintain social distancing recommendations. Patients reported more severe choking and coughing while eating during the COVID-19 pandemic and had a greater percentage weight loss from baseline, but the remainder of patient-reported outcomes and complications during radiotherapy were similar between the two cohorts.

Author contribution All contributed to this manuscript and reviewed the final version.

Funding This work was supported by Varian Medical Systems through an unrestricted grant.
Availability of data and material Data will not be shared due to privacy restrictions at our institution.

Code availability Not applicable.

Declarations

Ethics approval This study was approved by the UBC Research Ethics Board.

Consent to participate Not applicable.

Consent for publication Not applicable.

Competing interests SH, ET, JW, KD, VL, MC, and MC declare no competing interests. RO has received grants from Varian Medical Systems related to this work. EB has received grants and personal fees from Genzyme and Eisai outside the submitted work. NC reports honoraria from Bayer, Eisai, Merck, and Roche Canada; has served as a consultant or advisor to Bayer, Eisai, Lilly, Merck, and Roche; has received research funding from GlaxoSmithKline; and has received institutional research funding from Merck and Pfizer all outside the submitted work.

References

1. Niskanen JR, Halyard MY, Tan AD, Atherton PJ, Patel SH, Sloan JA (2017) Electronic patient-reported outcomes and toxicities during radiotherapy for head-and-neck cancer. Qual Life Res 26(7):1721–1731. https://doi.org/10.1007/s11136-017-1528-2
2. Falchook AD et al (2016) Comparison of patient- and practitioner-reported toxic effects associated with chemoradiotherapy for head and neck cancer. JAMA Otolaryngol - Head Neck Surg 142(6):517–523. https://doi.org/10.1001/jamaoto.2016.0656
3. Pusic A et al (2007) A systematic review of patient-reported outcome measures in head and neck cancer surgery. Otolaryngol - Head Neck Surg 136(4):525–535. https://doi.org/10.1016/j.otohns.2006.12.006
4. Wilkie JR et al (2019) Big data analysis of associations between patient reported outcomes, observer reported toxicities, and overall quality of life in head and neck cancer patients treated with radiation therapy. Radiother Oncol 137:167–174. https://doi.org/10.1016/j.radonc.2019.04.030
5. Ringash J (2015) Survivorship and quality of life in head and neck cancer. J Clin Oncol 33(29):3322–3327. https://doi.org/10.1200/JCO.2015.61.4115 (American Society of Clinical Oncology)
6. Tevetoglu F, Kara S, Aliyeva C, Yildirim R, Yener HM (2021) Delayed presentation of head and neck cancer patients during COVID-19 pandemic. Eur Arch Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-021-06728-2
7. Brody RM et al (2020) Changes in head and neck oncologic practice during the COVID-19 pandemic. Head Neck 42(7):1448–1453. https://doi.org/10.1002/hed.26233
8. Olson RA et al (2018) Provincial development of a patient-reported outcome initiative to guide patient care, quality improvement, and research. Healthc Manag Forum 31(1). https://doi.org/10.1177/0840470417715478
9. Holländer-Mieritz C, Johansen J, Johansen C, Vogelius IR, Kristensen CA, Pappot H (2019) Comparing the patients’ subjective experiences of acute side effects during radiotherapy for head and neck cancer with four different patient-reported outcomes questionnaires. Acta Oncol (Madr) 58(5):603–609. https://doi.org/10.1080/0284186X.2018.1563713
10. Rosenthal DI et al (2014) Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. Cancer 120(13):1975–1984. https://doi.org/10.1002/cncr.28672
11. Cleeland CS (2016) The M. D. Anderson Symptom Inventory User Guide. Version 1
12. Thomson DJ et al (2020) Practice recommendations for risk-adapted head and neck cancer radiation therapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement. Int J Radiat Oncol Biol Phys 107(4):618–627. https://doi.org/10.1016/j.ijrobp.2020.04.016
13. Sharma A, Crosby DL (2020) Special considerations for elderly patients with head and neck cancer during the COVID-19 pandemic. Head Neck 42(6):1147–1149. https://doi.org/10.1002/hed.26216
14. Prasad A, Brewster R, Newman JG, Rajasekaran K (2020) Optimizing your telemedicine visit during the COVID-19 pandemic: practice guidelines for patients with head and neck cancer. Head Neck 42(6):1317–1321. https://doi.org/10.1002/hed.26197
15. Langius JAE et al (2013) More than 10% weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life. Nutr Cancer 65(1):76–83. https://doi.org/10.1080/01635381.2013.741749
16. Hanna et al GJ (2021) Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 112. https://doi.org/10.1016/j.oraloncology.2020.105087
17. Ku PKM et al (2020) Management of dysphagia in the patient with head and neck cancer during COVID-19 pandemic: practical strategy. Head Neck 42(7):1491–1496. https://doi.org/10.1002/hed.26224
18. Nilsen ML et al (2020) Prevision of multidisciplinary head and neck cancer survivorship care during the 2019 novel coronavirus pandemic. Head Neck 42(7):1668–1673. https://doi.org/10.1002/hed.26256
19. Galio O et al (2021) The impact of the COVID-19 pandemic on the quality of life of head and neck cancer survivors. Support Care Cancer. https://doi.org/10.1007/s00520-021-06198-6
20. de Joode K et al (2020) Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective. Eur J Cancer 136:132–139. https://doi.org/10.1016/j.ejca.2020.06.019
21. Shaw R et al (2021) Head and neck cancer surgery during the COVID-19 pandemic: an international, multicenter, observational cohort study. Cancer 127(14):2476–2488. https://doi.org/10.1002/cncr.33320
22. Rygaliski CJ et al (2021) Time to surgery and survival in head and neck cancer. Ann Surg Oncol 28(2):877–885. https://doi.org/10.1245/s10434-020-09326-4
23. Chaves ALF et al (2020) Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic. Oral Oncology 107. Elsevier Ltd. https://doi.org/10.1016/j.oraloncology.2020.104734.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.